[Congressional Record Volume 172, Number 71 (Wednesday, April 22, 2026)]
[Senate]
[Pages S1960-S1961]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

  SA 4876. Ms. ROSEN submitted an amendment intended to be proposed by 
her to the concurrent resolution S. Con. Res. 33, setting forth the 
congressional budget for the United States Government for fiscal year 
2026 and setting forth the appropriate budgetary levels for fiscal 
years 2027 through 2035; which was ordered to lie on the table; as 
follows:

         At the end of title III, add the following:

     SEC. 3___. DEFICIT-NEUTRAL RESERVE FUND RELATING TO LOWERING 
                   PRESCRIPTION DRUG COSTS AND REDUCING DRUG 
                   SHORTAGES BY EXPANDING OPPORTUNITIES AND 
                   PATHWAYS FOR NONPROFIT PRESCRIPTION DRUG 
                   MANUFACTURERS TO EXPAND OPERATIONS WITHIN THE 
                   UNITED STATES.

         The Chairman of the Committee on the Budget of the Senate 
     may revise the allocations of a committee or committees, 
     aggregates, and other appropriate levels in this

[[Page S1961]]

     resolution, and make adjustments to the pay-as-you-go ledger, 
     for one or more bills, joint resolutions, amendments, 
     amendments between the Houses, motions, or conference reports 
     relating to lowering prescription drug costs and reducing 
     drug shortages by expanding opportunities and pathways for 
     nonprofit prescription drug manufacturers to expand 
     operations within the United States by the amounts provided 
     in such legislation for those purposes, provided that such 
     legislation would not increase the deficit over the period of 
     the total of fiscal years 2026 through 2035.
                                 ______